First CAR-T by Gilead and Kite Approved by FDA
Gilead Sciences and Kite Pharma's Yescarta (axicabtagene ciloleucel), the first chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with follicular lymphoma (FL). Follicular lymphoma is...
FDA Provides Guidance on Switches to Container Closure
The U.S. Food and Drug Administration (FDA) provided guidance that addresses changes to the supply chain due to COVID-19, including its regulatory process for manufacturing and controls (CMS) and chemistry. Materials like glass vials, stoppers, test swabs, and...
COA Translations: Empowering the Voice of Patients of Diverse Backgrounds
Over the last several years, patient-centricity has been a key theme in the healthcare sphere for improving drug therapies and medical devices for patients all around the world. To better serve patients, life science companies are putting in more effort on listening...
FDA Grants Fourth Breakthrough Device Designation for MedAlliance’s Sirolimus Drug-Eluting Balloon
The U.S. Food and Drug Administration (FDA) granted MedAlliance its fourth Breakthrough Device Designation for SELUTION SLR™, a sustained limus release drug-eluting balloon (DEB) catheter, to treat atherosclerotic lesions found in native coronary arteries. MedAlliance...
Boehringer Ingelheim and G1 Therapeutics Announce COSELA Now Commercially Available in US
Boehringer Ingelheim and G1 Therapeutics have announced that the injection of COSELA™ (trilaciclib) is now commercially available in the US. COSELA, the only U.S. Food and Drug Administration (FDA)-approved treatment that is meant to decrease the incidence of...
BridgeBio & Origin BioSciences’ Therapy for Rare Disease
The U.S. Food and Drug Administration (FDA) approved today NULIBRY™ (fosdenopterin), a treatment developed by BridgeBio and its affiliate Origin Biosciences for molybdenum cofactor deficiency (MoCD) Type A. MOCD Type A is an extremely rare metabolic disorder that...
FDA Clears IND Application for Flexion Therapeutics’ FX301
The U.S. Food and Drug Administration (FDA) cleared Flexion Therapeutics’ Investigational New Drug (IND) application for FX301, a locally administered NaV1.7 inhibitor for post-operative pain. The clearance came after the FDA reviewed preclinical data that was...
FDA Approves Targeted Treatment for Duchenne Muscular Dystrophy
The U.S. Food and Drug Administration (FDA) approved Amondys 45 (casimersen) injection from Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients that have a mutation amenable to skipping exon 45. DMD is a genetic disorder that causes...
FDA Partially Rescinds Two Supplemental Biologics License Applications
The Center for Biologics Evaluation and Research (CBER), part of the U.S. Food and Drug Administration (FDA), partially rescinded two approvals of supplemental biologics license applications (sBLAs) for recombinant factor IX products. The sBLAs were approved by the...
Sinopharm Unit and CanSinoBio apply for Public Use Approval of COVID-19 Vaccine in China
Sinopharm, a unit of the China National Pharmaceutical Group, and CanSinoBiologics Inc both have applied in China for the public use of their COVID-19 vaccines. Currently, China has two approved vaccines that were developed within the country, and has yet to approve...
FDA Makes Recommendations for COVID-19 Variants
The U.S. Food and Drug Administration (FDA) has revealed recommendations for drug developers and diagnostic test makers to address the efficacy and overall performance of their products in consideration of the COVID-19 variants. The updates in recommendations are...
FDA Clears Brainlab Loop-X Mobile Imaging Robot and Cirq Robotic Alignment Module
The U.S. Food and Drug Administration (FDA) cleared Brainlab’s Loop-X® Mobile Imaging Robot and Cirq®, a robotic surgical system. The clearance paves way for Brainlab to market in the U.S. market for both devices. Cirq robotic alignment module is meant for...
FDA Approves First Ever 3D-Printed Bone Replacement
The U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) has granted approval for the first customized 3D-printed bone replacement. The device, named Patient Specific Talus Spacer, is the only 3D-printed device in the world, and...
Translating TMFs for Global Clinical Trials
There is no doubt that clinical trials are vitally important in the drug development process. As an increasing number of clinical trials are conducted overseas, sometimes with multiple ongoing studies at once, having in-depth knowledge...
FDA Grants Novartis Entresto® Expanded Indication for Chronic Heart Failure
The U.S. Food and Drug Administration (FDA) has granted Novartis’ Entresto expanded indication for chronic heart failure, making it the only drug therapy approved in the US to treat patients afflicted with guideline-defined heart failure. Approximately 83% of...
OSE Immunotherapeutics Strengthens IPR for Anti-interleukin-7 Receptor (IL-7R) Antagonist OSE-127/S95011
OSE Immunotherapeutics, a clinical stage biotechnology company, announced today (2/17) that it was granted a patent by the European Patent Office (EPO) for its anti-interleukin-7 receptor (IL-7R) antagonist OSE-127/S95011. The patent, set to last until 2037, covers...
AstraZeneca-Oxford COVID-19 Vaccine is Granted EUA by WHO
The World Health Organization (WHO) announced yesterday (2/15) its approval of emergency use authorization (EUA) of the AstraZeneca-Oxford COVID-19 vaccine. The vaccine is currently approved in the UK and EU, and the WHO’s approval opens more doors for other nations...
FDA Grants EUA for New Molecular COVID-19 Diagnostic Test
The U.S. Food and Drug Administration (FDA) granted BD Emergency Use Authorization (EUA) for a new molecular diagnostic test for COVID-19 and the Influenza A+B virus that provides results within 2-3 hours. The test has already been CE marked for the IVD Directive....
FDA Issues EUA for Eli Lilly’s Antibody Combination for Mild to Moderate COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) the Eli Lilly’s etesevimab in combination with another AbCellera and Eli Lilly’s monoclonal antibody bamlanivimab for treating mild to moderate COVID-19 in patients 12 years or...
Pfizer Withdraws Application for EUA of COVID-19 Vaccine in India
Pfizer announced that it was withdrawing its application for emergency use authorization (EUA) in India for its COVID-19 vaccine. The pharmaceutical company failed to meet India’s regulatory requirements for a local immunogenicity study to ensure the safety of the...